

Rīga

2013 year 30 may

## **JSC "Rīgas Farmaceutiskā Fabrika"**

Unaudited statement of financial position

for year **2013.**

**I quart.**

**CONTENTS**

	<b>Lpp.</b>
<b>Data of the enterprise</b>	<b>3</b>
<b>Governing body report</b>	<b>4</b>
<b>Statement of comprehensive income (profit and loss account)</b>	<b>5</b>
<b>Balance sheet :</b>	<b>6</b>
<b>- assets</b>	<b>6</b>
<b>- liabilities</b>	<b>7</b>
<b>Statement of cash flow</b>	<b>8</b>
<b>Overview of equity capital changes</b>	<b>9</b>
<b>Notes to the financial statement</b>	<b>10</b>

**DATA OF THE ENTERPRISE**

Full name of the enterprise	JSC "Rīgas Farmaceutiskā Fabrika"
The legal status of a society	Joint-stock company
The state registration in the register of the enterprises	registration Nr. 40003000765 , Riga , 1991 year 26 march
The legal address of the enterprise	Duntes street 16/22 , Riga , LV-1005
Main activity of the company	Manufacture of pharmaceutical preparations
NACE code	21.20
Members of the board	Kaspars BĀLIŅŠ Uģis FREIMANIS Dace KALEINE
Councillors	Dagmāra ĀBOLTIŅA Jūlija DMITRIJEVA Vladimirs IVANIKINS Natalja GORBUNOVA Aksana BĒRZIŅA
The accounting period	from <b>01.01.2013</b> to <b>31.03.2013</b>

## MANAGEMENT REPORT

„Rīgas farmaceitiskā fabrika” JSC is located in Riga, 16/22 Dunties street and 6 Maza Ozolu street. The management of the company is realized by the Board of 3 persons.

The Company produce galenics products, therapeutically herbal teas and food supplies in Latvia. The factory was registered in the Register of Enterprises of the Republic of Latvia in 2004

The main types of operations of the company is the manufacturing of medicinal products, food supplies and medical goods. The finished products mainly were distributed in Latvia.

We have started to change design of Dr.Pakalns teas in 1st quarter. Previously existed linen bags are gradually replaced with modern, bright and for consumers’ handy corrugated fibreboard cardboard boxes cubes. Now tea storage and usage is much more convenient. Reviewing tea drinking habits, we have added to label tea making recommendations for hurry people.

We have rebuilt our home page [www.rff.lv](http://www.rff.lv) starting this year. Our web page is modernized and made much more user-friendly and foreseeable. Here you can learn about all ongoing monthly special offers in local pharmacies chains, as well as get more depth information on each of our manufactured products. We have also started activities in different social networks- locals and internationals.

The neto turnover of the company in 3 mounth 2013 was **484 340 EUR** ( 340 396 LVL ). The profit of the company in 2013 was **23 270 EUR** ( 16 354 LVL ).

The management of joint stock company „Rīgas farmaceitiskā fabrika” is liable for the preparation of financial report and it is liable, that financial reports are prepared according to requirements of valid legislative acts and provides the true and clear conception about the assets, liabilities, financial situation and profit or losses, as well as for the fact that the management report includes true information.

The management of the company is liable about corresponding provision of bookkeeping system, the maintenance of the Company’s assets, as well as for the prevention and detection of the fraud and other irregularities in the Company. The management is also responsible for the accomplishment of Latvian legislation.

  
Kaspars BĀLINŠ

  
Uģis FREĪMANIS

  
Dace KALEĪNE

---

---

2013 year 30 may


**STATEMENT OF COMPREHENSIVE INCOME for the period ended 31.03.2013**

		2013.	2013.	2012.	2012.
		I quart.	I quart.	I quart.	I quart.
		LVL	EUR	LVL	EUR
Net turnover	2	340 396	484 340	503 455	716 352
Cost of sales (prime cost)	3	-165 716	-235 793	-308 603	-439 103
<b>Gross profit or loss</b>		<b>174 680</b>	<b>248 547</b>	<b>194 852</b>	<b>277 249</b>
Sales distribution costs	4	-121 053	-172 243	-104 627	-148 871
Administration costs	5	-30 890	-43 953	-52 938	-75 324
Other operating income	6	1 192	1 696	-760	-1 081
Other operating expenses	7	-6 962	-9 906	-8 694	-12 370
Interest payable and similar charges	8	-262	-373	0	0
<b>Peļņa vai zaudējumi pirms ārkārtas posteņiem un nodokļiem</b>		<b>16 705</b>	<b>23 768</b>	<b>27 833</b>	<b>39 603</b>
Corporate income tax (postpone)		0	0	0	0
Other taxes	9	-351	-499	-595	-847
<b>Profit or loss for the financial period</b>		<b>16 354</b>	<b>23 270</b>	<b>27 238</b>	<b>38 756</b>
<b>EPS k-t</b>		<b>0,0247</b>	<b>0,0351</b>	<b>0,0411</b>	<b>0,0585</b>


Annex from 10 . to 19 . is an integral part of these financial statements



Kaspars BĀLINŠ



Uģis FREIMANIS



Dace KALEINE

2013 year 30 may

JSC "Rīgas Farmaceutiskā Fabrika" year 2013  
FINANCIAL REPORT

**BALANCE SHEET for the period ended**

**31.03.2013**

**ASSETS**

		<b>2013.</b>	<b>2013.</b>	<b>2012.</b>	<b>2012.</b>
		<b>I quart.</b>	<b>I quart.</b>	<b>I quart.</b>	<b>I quart.</b>
		<b>LVL</b>	<b>EUR</b>	<b>LVL</b>	<b>EUR</b>
<b>Long - term investments</b>					
<b>Intangible investments</b>					
Concessions, patents, licenses, trade-marks and similar rights	10	14 700	20 916	25 868	36 807
Advance payments of intangible investments		0	0	0	0
<b>TOTALLY</b>		<b>14 700</b>	<b>20 916</b>	<b>25 868</b>	<b>36 807</b>
<b>Fixed assets</b>					
Lands, buildings, constructions and pre-nial plantations	11	309 476	440 345	354 624	504 584
Technological equipment and machines	11	82 748	117 740	75 644	107 632
Other fixed assets and inventory	11	17 847	25 394	26 411	37 579
Advance payments for fixed assets		0	0	0	0
<b>TOTALLY</b>		<b>410 071</b>	<b>583 478</b>	<b>456 679</b>	<b>649 796</b>
<b>Long - term investments</b>	<b>TOTALLY</b>	<b>424 771</b>	<b>604 395</b>	<b>482 547</b>	<b>686 603</b>
<b>Current assets</b>					
<b>Stocks</b>					
Raw materials, direct materials and auxiliary materials	12	240 348	341 984	246 119	350 196
Unfinished products	13	31 945	45 454	32 881	46 785
Complete products and goods for sale	14	142 611	202 917	37 456	53 295
Advance payments for goods		13 379	19 037	614	874
Work animals and productive animals	15	150	213	150	213
<b>TOTALLY</b>		<b>428 433</b>	<b>609 605</b>	<b>317 220</b>	<b>451 363</b>
<b>Debtors</b>					
Customers and client debts	16	50 427	71 751	81 149	115 465
Other debts	17	291	414	46 044	65 515
Accured income	18	11 704	16 653	12 514	17 806
<b>TOTALLY</b>		<b>62 422</b>	<b>88 819</b>	<b>139 707</b>	<b>198 785</b>
<b>Cash assets</b>	19	4 329	6 160	1 543	2 195
<b>Current assets</b>	<b>TOTALLY</b>	<b>495 184</b>	<b>704 583</b>	<b>458 470</b>	<b>652 344</b>
<b>BALANCE</b>		<b>919 955</b>	<b>1 308 978</b>	<b>941 017</b>	<b>1 338 947</b>


**BALANCE SHEET for the period ended 31.03.2013**

LIABILITIES		2013.	2013.	2012.	2012.
		I quart.	I quart.	I quart.	I quart.
		LVL	EUR	LVL	EUR
<b>Equity capital</b>					
Stock or share capital (equity capital)	20	663 000	943 364	663 000	943 364
Retained profit:					
a) Retained profit of previous years		-34 384	-48 924	-58 401	-83 097
b) Retained profit of the year of accountant	21	16 354	23 270	27 238	38 756
<b>TOTALLY</b>		<b>644 970</b>	<b>917 710</b>	<b>631 837</b>	<b>899 023</b>
<b>Stockpiles</b>					
Other stockpiles	22	20 737	29 506	20 938	29 792
<b>TOTALLY</b>		<b>20 737</b>	<b>29 506</b>	<b>20 938</b>	<b>29 792</b>
<b>Creditors</b>					
<b>Long - term debts</b>					
Other loans	23	25 093	35 704	0	0
Tax on profit (pustpone) or loss for the financial period	27	0	0	13 355	19 002
<b>TOTALLY</b>		<b>25 093</b>	<b>35 704</b>	<b>13 355</b>	<b>19 002</b>
<b>Short - term debts</b>					
Other loans	23	14 545	20 696	0	0
Debts to suppliers and contractors	24	137 235	195 268	228 415	325 005
Tax and social security payments	25	21 681	30 849	31 147	44 318
Other creditors	26	12 894	18 347	12 485	17 765
Accrued liabilities	28	42 800	60 899	2 840	4 041
<b>TOTALLY</b>		<b>229 155</b>	<b>326 058</b>	<b>274 887</b>	<b>391 129</b>
<b>Creditors TOTALLY</b>		<b>254 248</b>	<b>361 762</b>	<b>288 242</b>	<b>410 131</b>
<b>BALANCE</b>		<b>919 955</b>	<b>1 308 978</b>	<b>941 017</b>	<b>1 338 947</b>

Annex from 10. to 19. is an integral part of these financial statements

  
Kaspars BĀLINŠ

  
Uģis FREIMANIS



2013 year 30 may

**STATEMENT OF CASH FLOW for the period ended 31.03.2013**  
**(indirect method)**

	2013. I quart. LVL	2013. I quart. EUR	2012. I quart. LVL	2012. I quart. EUR
<b>CASH FLOW from operating activities</b>				
<b>Profit or loss before extraordinary items and tax</b>	<b>16 705</b>	<b>23 769</b>	<b>27 833</b>	<b>39 603</b>
Corrections :				
depreciation of fixed assets and intangible investments (+)	28 175	40 089	30 800	43 824
accumulation for unused vacation (+)	0	0	0	0
interest payable and similar charges (+)	262	373	0	0
<b>Profit or loss before working capital and working capital correction influence</b>	<b>45 142</b>	<b>64 231</b>	<b>58 633</b>	<b>83 427</b>
Corrections :				
debts of customers and subscribers	10 371	14 757	42 539	60 528
provisions	-120 774	-171 846	15 095	21 478
others debtors	75 225	107 036	-108 571	-154 483
<b>Net cash provided by operating activities</b>	<b>9 964</b>	<b>14 177</b>	<b>7 696</b>	<b>10 950</b>
interest payments (-)	-262	-373	0	0
the taxes deducted from net profit (property tax)	-351	-499	-595	-847
<b>Cash flow from operating activities</b>	<b>9 351</b>	<b>13 305</b>	<b>7 101</b>	<b>10 104</b>
<b>Investing activities</b>				
fixed assets purchase costs	-2 481	-3 530	-6 444	-9 169
income from sale of fixed assets	0	0	0	0
<b>Cash provided by investing activities</b>	<b>-2 481</b>	<b>-3 530</b>	<b>-6 444</b>	<b>-9 169</b>
<b>Cash flow from financing</b>				
Expenses of leased fixed assets (-)	-4 822	-6 861	0	0
<b>Net financing cash flow</b>	<b>-4 822</b>	<b>-6 861</b>	<b>0</b>	<b>0</b>
<b>Net increase (decrease) in cash</b>	<b>2 048</b>	<b>2 914</b>	<b>657</b>	<b>935</b>
<b>Cash at the beginning of the year</b>	<b>2 281</b>	<b>3 246</b>	<b>886</b>	<b>1 261</b>
<b>Cash at the end of the year</b>	<b>4 329</b>	<b>6 160</b>	<b>1 543</b>	<b>2 195</b>

Annex from 10. to 19. is an integral part of these financial statements

  
Kaspars BĀLIŅŠ

  
Uģis FREIMANIS

  
Dace KALEINE

2013 year 30 may




**OVERVIEW of EQUITY CAPITAL CHANGES**  
**for the period ended 31.03.2013**

	Share capital		Reserves		Retained profit of previous years		Retained profit of the year of accountant		Equity capital (total)	
	LVL	EUR	LVL	EUR	LVL	EUR	LVL	EUR	LVL	EUR
<b>01.01.2012</b>	<b>663 000</b>	<b>943 364</b>	<b>0</b>	<b>0</b>	<b>-67 030</b>	<b>-95 375</b>	<b>8 628</b>	<b>12 277</b>	<b>604 598</b>	<b>860 265</b>
2011 year profit transferred to retained earnings					8 628	12 277	-8 628	-12 277	-	-
Retained profit of the year of accountant							24 017	34 173	24 017	34 173
Relief for losses from reserves									-	-
<b>31.12.2012</b>	<b>663 000</b>	<b>943 364</b>	<b>-</b>	<b>-</b>	<b>-58 401</b>	<b>-83 097</b>	<b>24 017</b>	<b>34 173</b>	<b>628 616</b>	<b>894 440</b>
2012 year profit transferred to retained earnings					24 017	34 173	-24 017	-34 173	-	-
Retained profit of the year of accountant							16 354	23 270	16 354	23 270
<b>31.03.2013</b>	<b>663 000</b>	<b>943 364</b>	<b>-</b>	<b>-</b>	<b>-34 384</b>	<b>-48 924</b>	<b>16 354</b>	<b>23 270</b>	<b>644 970</b>	<b>917 710</b>


Annex from 10. līdz 10. to 19. is an integral part of these financial statements



Kaspars BĀLINŠ



Uģis FREIĻMANIS



Dace KALEĪNE

2013 year 30 may

## (1) STATEMENT OF ACCOUNTING POLICIES - GENERAL PRINCIPLES

### Basis of preparation

The Annual Report is prepared in accordance with Latvian law "On Accounting" and "Annual reports".

The income statement is prepared in accordance with the turnover method.

The cash flow statement prepared using the indirect method.

### Net sales

Net sales represent the revenues of the company's core business, the sale of products and services, net of trade discount and other discounts granted, as well as value added tax and other taxes directly related to the sale.

Proceeds from the sale of goods is recognized when the buyer s accepted the goods, according to delivery terms.

### During the reporting period

The reporting period is 3 months of 01.01.2013 to 31.03.2013 .

### Currency and foreign currency translation

These financial statements are expressed in the Latvian national currency - Lats (LVL) and euro (EUR).

All monetary assets and liabilities are translated into Latvian lats at the exchange rate at the period end.

	31.03.2013	31.12.2012
USD	-	-
EUR	0,702804	0,702804

Foreign exchange rate fluctuations on profit or loss is reflected in the profit and loss account.

### Long-term and short-term items

Long-term items of an amount reported by the receipt, payment, or write-off shall be the later of one year after the year end.

The amounts received, paid or written off during the reported short-term positions.

### Non-current assets and depreciation recognition

Balance sheet of all fixed assets and intangible assets are stated at cost less depreciation rates.

Depreciation is calculated on straight-line methods,

choosing on the basis of the following rates:

#### *Intangible assets:*

license	20	%
other intangible assets	20	%

#### *Fixed Assets:*

Buildings and structures	5-10	%
Iekārtas un mašīnas		%

Язык оригинала: английский

Введите текст или адрес веб-сайта либо переведите документ.

Отмена

латышскийанглийскийрусскийAlpha

Equipment and machinery	20	
Other fixed assets	20-35	%

**Measurement of inventories**

Reserves are estimated using FIFO method.  
Inventory balances checked on the inventory.

**Receivables**

Trade receivables are shown net of.

**Savings**

Provisions are intended to cover certain types of obligations, relating to the reporting year or previous years and Annual Reports of the anticipated or known, but the amount or specific commitment to the creation or the date of recovery is uncertain.

**Provision for vacation pay**

Amount of the provision is determined by multiplying the average employee salary of one day to the year-end accrued but unused vacation days.

**Accrued liabilities**

Clearly aware of the settlement amount payable for the current year goods or services received if the balance sheet date has not yet received the corresponding payment document in accordance with the supply, sale or contract business conditions or other reasons, recognized as accruals for the period.

**Corporate income tax**

Corporate income tax costs are included in the financial statements in accordance with Latvian tax legislation of.

For the reporting period the estimated tax is calculated under the Law "On Corporate Income Tax " 'claims in determining taxable income, and applying the statutory tax rate of 15%.

JSC "Rīgas Farmaceutiskā Fabrika" year 2013  
FINANCIAL REPORT

**(2) Net Sales**

Type of activity	2013.	2013.	2012.	2012.
	LVL	EUR	LVL	EUR
Manufacture of drugs	325 347	462 927	489 174	696 032
Raw materials and distribution	5 216	7 422	7 053	10 036
Provision of services	9 833	13 991	7 228	10 285
<b>Total</b>	<b>340 396</b>	<b>484 340</b>	<b>503 455</b>	<b>716 352</b>

**Net sales by geographical markets**

State	2013.	2013.	2012.	2012.
	LVL	EUR	LVL	EUR
Latvia	305 390	434 531	479 210	681 854
Lithuania	5 393	7 674	8 625	12 272
Estonia	29 613	42 136	15 620	22 225
Other	0	0	0	0
<b>Total</b>	<b>340 396</b>	<b>484 340</b>	<b>503 455</b>	<b>716 352</b>

**(3) Cost of sales**

	2013.	2013.	2012.	2012.
	LVL	EUR	LVL	EUR
Cost of materials	46 553	66 239	179 227	255 017
Staff costs	26 984	38 395	28 805	40 986
State social security contributions	6 337	9 017	6 772	9 636
Depreciation of fixed assets and intangible assets depreciation	28 175	40 089	30 800	43 824
Depreciation of current assets	975	1 387	2 042	2 906
Maintenance costs	33 210	47 254	36 096	51 360
Transport costs	8 386	11 932	6 741	9 592
Other	15 096	21 480	18 120	25 782
<b>Total</b>	<b>165 716</b>	<b>235 793</b>	<b>308 603</b>	<b>439 103</b>

**(4) Sales expenses**

	2013.	2013.	2012.	2012.
	LVL	EUR	LVL	EUR
Staff costs	47 460	67 529	46 095	65 587
State social security contributions	11 024	15 686	10 706	15 233
Advertising expenses	59 883	85 206	43 220	61 497
Transport costs	1 726	2 456	1 591	2 264
Other	960	1 366	3 015	4 290
<b>Total</b>	<b>121 053</b>	<b>172 243</b>	<b>104 627</b>	<b>148 871</b>

**(5) Administration costs**

	<b>2013.</b>	<b>2013.</b>	<b>2012.</b>	<b>2012.</b>
	<b>LVL</b>	<b>EUR</b>	<b>LVL</b>	<b>EUR</b>
Staff costs	14 080	20 034	11 947	16 999
State social security contributions	3 373	4 799	2 879	4 096
Legal and accounting services	1 006	1 431	6 644	9 454
Transport costs	2 432	3 460	2 236	3 182
Other	9 999	14 227	29 232	41 593
<b>Total</b>	<b>30 890</b>	<b>43 953</b>	<b>52 938</b>	<b>75 324</b>

**(6) Other operating income**

	<b>2013.</b>	<b>2013.</b>	<b>2012.</b>	<b>2012.</b>
	<b>LVL</b>	<b>EUR</b>	<b>LVL</b>	<b>EUR</b>
The difference of exchange rate changes and currency sales	112	159	-760	-1 081
Received a penalty	527	750	0	0
Proceeds from sale of fixed assets	0	0	0	0
Other	553	787	0	0
<b>Total</b>	<b>1 192</b>	<b>1 696</b>	<b>-760</b>	<b>-1 081</b>

**(7) Other operating expenses**

	<b>2013.</b>	<b>2013.</b>	<b>2012.</b>	<b>2012.</b>
	<b>LVL</b>	<b>EUR</b>	<b>LVL</b>	<b>EUR</b>
Expenses not related to economic activity	6 492	9 237	8 607	12 247
The difference of exchange rate changes and currency sales	0	0	0	0
Penalties	20	28	0	0
Gifts and benefits	150	213	0	0
Other	300	427	87	124
<b>Total</b>	<b>6 962</b>	<b>9 906</b>	<b>8 694</b>	<b>12 370</b>

**(8) Interest payable and similar charges**

	<b>2013.</b>	<b>2013.</b>	<b>2012.</b>	<b>2012.</b>
	<b>LVL</b>	<b>EUR</b>	<b>LVL</b>	<b>EUR</b>
Leasing interest payments	262	373	0	0
<b>Total</b>	<b>262</b>	<b>373</b>	<b>0</b>	<b>0</b>

**(9) Other taxes**

	<b>2013.</b>	<b>2013.</b>	<b>2012.</b>	<b>2012.</b>
	<b>LVL</b>	<b>EUR</b>	<b>LVL</b>	<b>EUR</b>
Real estates tax	351	499	595	847
<b>Total</b>	<b>351</b>	<b>499</b>	<b>595</b>	<b>847</b>

JSC "Rīgas Farmaceutiskā Fabrika" year 2013  
FINANCIAL REPORT

(9) Intangible assets

	Licenses and patents		Advance payment for intangible assets		Total intangible assets	
	LVL	EUR	LVL	EUR	LVL	EUR
<b>Historical cost as of</b>						
<b>31.12.2012</b>	<b>99 417</b>	<b>141 458</b>	<b>0</b>	<b>0</b>	<b>99 417</b>	<b>141 458</b>
Additions	0	0	0	0	0	0
Disposals	0	0	0	0	0	0
<b>31.03.2013</b>	<b>99 417</b>	<b>141 458</b>	<b>0</b>	<b>0</b>	<b>99 417</b>	<b>141 458</b>
Accumulated depreciation before						
<b>31.12.2012</b>	<b>81 920</b>	<b>116 562</b>	<b>0</b>	<b>0</b>	<b>81 920</b>	<b>116 562</b>
Accumulated depreciation	2 797	3 980	0	0	2 797	3 980
<b>31.03.2013</b>	<b>84 717</b>	<b>120 541</b>	<b>0</b>	<b>0</b>	<b>84 717</b>	<b>120 541</b>
<b>Net book value 31.12.2012</b>	<b>17 497</b>	<b>24 896</b>	<b>0</b>	<b>0</b>	<b>28 704</b>	<b>40 842</b>
<b>Net book value 31.03.2013</b>	<b>14 700</b>	<b>20 916</b>	<b>0</b>	<b>0</b>	<b>14 700</b>	<b>20 916</b>

JSC "Rīgas Farmaceutiskā Fabrika" year 2013  
FINANCIAL REPORT

(11) Fixed assets

	Land and buildings		Equipment		Other fixed assets		Advance payment for fixed assets		Fixed assets total	
	LVL	EUR	LVL	EUR	LVL	EUR	LVL	EUR	LVL	EUR
<b>Historical cost as of</b>										
<b>31.12.2012</b>	<b>649 072</b>	<b>923 546</b>	<b>578 013</b>	<b>822 438</b>	<b>247 854</b>	<b>352 664</b>	-	-	<b>1 474 939</b>	<b>2 098 649</b>
Additions	0	0	0	0	2 481	3 530	0	0	2 481	3 530
Disposals	0	0	0	0	-2 760	-3 927	0	0	-2 760	-3 927
<b>31.03.2013</b>	<b>649 072</b>	<b>923 546</b>	<b>578 013</b>	<b>822 438</b>	<b>247 575</b>	<b>352 267</b>	<b>0</b>	<b>0</b>	<b>1 474 660</b>	<b>2 098 252</b>
Accumulated depreciation before										
<b>31.12.2012</b>	<b>328 309</b>	<b>467 142</b>	<b>483 280</b>	<b>687 645</b>	<b>230 382</b>	<b>327 804</b>	-	-	<b>1 041 971</b>	<b>1 482 591</b>
Accumulated depreciation	11 287	16 060	11 985	17 053	2 106	2 997	0	0	25 378	36 110
Excluded on disposal	0	0	0	0	-2 760	-3 927	0	0	-2 760	-3 927
<b>31.03.2013</b>	<b>339 596</b>	<b>483 202</b>	<b>495 265</b>	<b>704 699</b>	<b>229 728</b>	<b>326 873</b>	<b>0</b>	<b>0</b>	<b>1 064 589</b>	<b>1 514 774</b>
<b>Net book value 31.12.2012</b>	<b>320 763</b>	<b>456 405</b>	<b>94 733</b>	<b>134 793</b>	<b>17 472</b>	<b>24 860</b>	<b>0</b>	<b>0</b>	<b>432 968</b>	<b>616 058</b>
<b>Net book value 31.03.2013</b>	<b>309 476</b>	<b>440 345</b>	<b>82 748</b>	<b>117 740</b>	<b>17 847</b>	<b>25 394</b>	<b>0</b>	<b>0</b>	<b>410 071</b>	<b>583 478</b>

**(12) Raw materials, direct materials and auxiliary materials**

	<b>2013.</b>	<b>2013.</b>	<b>2012.</b>	<b>2012.</b>
	<b>LVL</b>	<b>EUR</b>	<b>LVL</b>	<b>EUR</b>
Materials	118 853	169 113	86 142	122 569
Consumables - glass containers	51 840	73 762	110 754	157 589
Consumables - plastic and metal packages	47 932	68 201	19 689	28 015
Printed materials	12 829	18 254	29 534	42 023
Other	8 894	12 655	0	0
<b>Total</b>	<b>240 348</b>	<b>341 984</b>	<b>246 119</b>	<b>350 196</b>

**(13) Unfinished products**

	<b>2013.</b>	<b>2013.</b>	<b>2012.</b>	<b>2012.</b>
	<b>LVL</b>	<b>EUR</b>	<b>LVL</b>	<b>EUR</b>
The packing station neizfasēta products (quarantine area)	21 003	29 885	27 825	39 591
Production units of semi-finished products segment	10 942	15 569	5 056	7 194
<b>Total</b>	<b>31 945</b>	<b>45 454</b>	<b>32 881</b>	<b>46 785</b>

**(14) Complete products and goods for sale**

	<b>2013.</b>	<b>2013.</b>	<b>2012.</b>	<b>2012.</b>
	<b>LVL</b>	<b>EUR</b>	<b>LVL</b>	<b>EUR</b>
The company's stock of finished goods in stock	142 611	202 917	37 456	53 295
<b>Total</b>	<b>142 611</b>	<b>202 917</b>	<b>37 456</b>	<b>53 295</b>

**(15) Work animals and productive animals**

	<b>2013.</b>	<b>2013.</b>	<b>2012.</b>	<b>2012.</b>
	<b>LVL</b>	<b>EUR</b>	<b>LVL</b>	<b>EUR</b>
Guard dogs	150	213	150	213
<b>Total</b>	<b>150</b>	<b>213</b>	<b>150</b>	<b>213</b>

**(16) Customers and client debts**

	<b>2013.</b>	<b>2013.</b>	<b>2012.</b>	<b>2012.</b>
	<b>LVL</b>	<b>EUR</b>	<b>LVL</b>	<b>EUR</b>
Trade receivables have a carrying amount	50 427	71 751	81 149	115 465
<b>Book value</b>	<b>50 427</b>	<b>71 751</b>	<b>81 149</b>	<b>115 465</b>

By currencies :

	<b>2013.</b>			<b>2012.</b>		
	<b>currency</b>	<b>LVL</b>	<b>EUR</b>	<b>currency</b>	<b>LVL</b>	<b>EUR</b>
LVL	22 477	22 477	31 982	81 149	81 149	115 465
EUR	39 769	27 950	39 769	0	0	0
Other	0	0	0	0	0	0
<b>Total</b>		<b>50 427</b>	<b>71 751</b>		<b>81 149</b>	<b>115 465</b>



JSC "Rīgas Farmaceutiskā Fabrika" year 2013  
FINANCIAL REPORT

**(17) Other debts**

	<b>2013.</b>	<b>2013.</b>	<b>2012.</b>	<b>2012.</b>
	<b>LVL</b>	<b>EUR</b>	<b>LVL</b>	<b>EUR</b>
Tax receivables together	0	0	44 971	63 988
Operatīvā līzīngā neamortizētās daļas of settlement balances	291	414	1 073	1 527
<b>Total</b>	<b>291</b>	<b>414</b>	<b>46 044</b>	<b>65 515</b>

**(18) Accrued income**

	<b>2013.</b>	<b>2013.</b>	<b>2012.</b>	<b>2012.</b>
	<b>LVL</b>	<b>EUR</b>	<b>LVL</b>	<b>EUR</b>
Property Insurance	4 522	6 434	3 640	5 179
Vehicle Insurance	629	895	2 103	2 992
Employee Health Insurance	5 941	8 453	6 198	8 819
Magazine subscription	264	376	274	390
Other	348	495	299	425
<b>Total</b>	<b>11 704</b>	<b>16 653</b>	<b>12 514</b>	<b>17 806</b>

**(19) Cash Assets and EUR currency according to the 31.12.**

By currencies :	<b>2013.</b>			<b>2012.</b>		
	<b>currency</b>	<b>LVL</b>	<b>EUR</b>	<b>currency</b>	<b>LVL</b>	<b>EUR</b>
LVL	4 106	4 106	5 842	1 543	1 543	2 195
EUR	317	223	317	0	0	0
Other	0	0	0	0	0	0
<b>Total</b>		<b>4 329</b>	<b>6 160</b>		<b>1 543</b>	<b>2 195</b>

**(20) Share capital**

	663 000	LVL,	943 364	EUR
consisting of	660 000			ordinary shares with voting rights
and	3 000			common shares without voting rights
Each share is LVL	1		EUR 1,4229	

**(21) Retained earnings**

	<b>LVL</b>	<b>EUR</b>
For 2013. the reporting year, the profits up	<b>16 354</b>	<b>23 270</b>

**(22) Other provisions**

	<b>2013.</b>	<b>2013.</b>	<b>2012.</b>	<b>2012.</b>
	<b>LVL</b>	<b>EUR</b>	<b>LVL</b>	<b>EUR</b>
Provision for unused vacations	20 737	29 506	20 938	29 792
<b>Total</b>	<b>20 737</b>	<b>29 506</b>	<b>20 938</b>	<b>29 792</b>

**Long-term debts**

	<b>2013.</b>	<b>2013.</b>	<b>2012.</b>	<b>2012.</b>
	<b>LVL</b>	<b>EUR</b>	<b>LVL</b>	<b>EUR</b>
(23) Other loans	25 093	35 704	0	0
<b>Total</b>	<b>25 093</b>	<b>35 704</b>	<b>0</b>	<b>0</b>

**Short-term debts**

	<b>2013.</b>	<b>2013.</b>	<b>2012.</b>	<b>2012.</b>
	<b>LVL</b>	<b>EUR</b>	<b>LVL</b>	<b>EUR</b>
(23) Other loans	14 545	20 696	0	0
<b>Total</b>	<b>14 545</b>	<b>20 696</b>	<b>0</b>	<b>0</b>

	<b>2013.</b>	<b>2013.</b>	<b>2012.</b>	<b>2012.</b>
	<b>LVL</b>	<b>EUR</b>	<b>LVL</b>	<b>EUR</b>
(27) Tax on profit (pustpone) or loss for the financial period	0	0	13 355	19 002
<b>Total</b>	<b>0</b>	<b>0</b>	<b>13 355</b>	<b>19 002</b>

**(24) Trade and other payables**

<b>Current portion of</b>	<b>2013.</b>	<b>2013.</b>	<b>2012.</b>	<b>2012.</b>
	<b>LVL</b>	<b>EUR</b>	<b>LVL</b>	<b>EUR</b>
Trade and other payables the carrying amount of	137 235	195 268	228 415	325 005
<b>Total</b>	<b>137 235</b>	<b>195 268</b>	<b>228 415</b>	<b>325 005</b>

<b>Current portion of</b>	<b>2013.</b>			<b>2012.</b>			
	<b>By currencies :</b>	<b>currency</b>	<b>LVL</b>	<b>EUR</b>	<b>currency</b>	<b>LVL</b>	<b>EUR</b>
LVL		102 725	102 725	146 165	173 186	173 186	246 421
EUR		49 103	34 510	49 103	78 584	55 229	78 584
Other		0	0	0	0	0	0
<b>Total</b>		<b>137 235</b>	<b>195 268</b>		<b>228 415</b>	<b>325 005</b>	

JSC "Rīgas Farmaceutiskā Fabrika" year 2013  
FINANCIAL REPORT

**(25) Current portion of**

	<b>2013.</b>	<b>2013.</b>	<b>2012.</b>	<b>2012.</b>
	<b>LVL</b>	<b>EUR</b>	<b>LVL</b>	<b>EUR</b>
Corporate income tax	0	0	0	0
Value-added tax	5 899	8 394	11 952	17 006
State social security contributions	9 939	14 142	10 029	14 270
Personal income tax	5 685	8 089	5 974	8 500
Business risk charge	16	23	16	23
Natural resource tax	142	202	0	0
Nekustamā īpašuma nodoklis	0	0	3 176	4 519
<b>Total</b>	<b>21 681</b>	<b>30 849</b>	<b>31 147</b>	<b>44 318</b>

**(26) Current portion of**

	<b>2013.</b>	<b>2013.</b>	<b>2012.</b>	<b>2012.</b>
	<b>LVL</b>	<b>EUR</b>	<b>LVL</b>	<b>EUR</b>
Wage debt	12 894	18 347	12 485	17 765
<b>Total</b>	<b>12 894</b>	<b>18 347</b>	<b>12 485</b>	<b>17 765</b>

**(28) Accrued liabilities**

	<b>2013.</b>	<b>2013.</b>	<b>2012.</b>	<b>2012.</b>
	<b>LVL</b>	<b>EUR</b>	<b>LVL</b>	<b>EUR</b>
Accrued discounts will be	40 000	56 915	0	0
Other	2 800	3 984	2 840	4 041
<b>Total</b>	<b>42 800</b>	<b>60 899</b>	<b>2 840</b>	<b>4 041</b>

**(29) Number of employees**

	<b>2013.</b>	<b>2012.</b>
The average number of persons employed by the company	63	64

**(30) News about events after the balance sheet date**

In the period since the last days before the reporting date is no significant events that could materially affect the results of the annual report.